ACADIA Pharmaceuticals Inc. Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 2020 Annual Meeting of Stockholders June 23, 2020 10:00 AM ET Company Participants Steve Biggar - Chairman of the Boar

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report),

Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential

US Bancorp DE grew its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 48.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional inv

For those that thought the extreme market volatility was behind us, think again. Last week, another burst of volatility was brought on by concerns about the U.S. economic recovery and a second wave of

In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Neurocrine (NBIX – Research Report), with

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma

Needham analyst Alan Carr assigned a Hold rating to Neurocrine (NBIX – Research Report) today. The company’s shares closed last

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

Acadia Pharmaceuticals Inc. (ACAD) has announced that it has filed a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration

In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Incyte (INCY – Research Report), with

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential n

In a report released today, Alan Carr from Needham assigned a Buy rating to Crispr Therapeutics AG (CRSP – Research

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).